GlassScriptPhysician profile
Holly Hart
NPI 1902566326
$1,765.38
in general payments reported to CMS, 2019-2025
15 companies · $13.93 in 2025
The $13.93 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,200 · 2023: $311 · 2024: $240 · 2025: $13.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.98 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $205.83 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $172.03 | 2022 | |
| Neurocrine Biosciences, INC. | $140.84 | 2022-2023 | |
| Neos Therapeutics, LP | $123.45 | 2022 | |
| Corium, LLC | $105.88 | 2022 | |
| Eisai INC. | $95.11 | 2022 | |
| Merck Sharp & Dohme LLC | $87.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.29 | 2022 | |
| Almatica Pharma LLC | $39.59 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.15 | 2022-2025 | Caplyta |
| Lundbeck LLC | $34.96 | 2022 | |
| Indivior INC. | $25.70 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.25 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.